Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 5.3% – Should You Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s share price shot up 5.3% on Friday . The company traded as high as $7.68 and last traded at $7.59. 5,773,886 shares were traded during mid-day trading, a decline of 46% from the average session volume of 10,779,051 shares. The stock had previously closed at $7.21.

Analyst Ratings Changes

Separately, Needham & Company LLC reissued a “buy” rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $9.25.

Recursion Pharmaceuticals Stock Up 6.8 %

The firm has a market capitalization of $3.01 billion, a PE ratio of -5.03 and a beta of 0.85. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock has a 50 day simple moving average of $6.84 and a 200 day simple moving average of $7.09.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). The firm had revenue of $26.08 million for the quarter, compared to the consensus estimate of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company’s quarterly revenue was up 147.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.43) earnings per share. As a group, sell-side analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Insider Transactions at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CFO Michael Secora sold 15,000 shares of the company’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total value of $114,900.00. Following the completion of the transaction, the chief financial officer now directly owns 1,499,631 shares in the company, valued at approximately $11,487,173.46. This represents a 0.99 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $6.67, for a total transaction of $76,351.49. Following the completion of the sale, the director now directly owns 7,089,007 shares of the company’s stock, valued at approximately $47,283,676.69. This represents a 0.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 70,341 shares of company stock worth $488,290. Company insiders own 15.75% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in RXRX. GAMMA Investing LLC boosted its holdings in shares of Recursion Pharmaceuticals by 1,979.2% during the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock valued at $35,000 after buying an additional 4,948 shares in the last quarter. JPMorgan Chase & Co. lifted its position in Recursion Pharmaceuticals by 6.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,176,191 shares of the company’s stock valued at $7,751,000 after acquiring an additional 67,464 shares during the period. Franklin Resources Inc. boosted its stake in Recursion Pharmaceuticals by 58.9% during the third quarter. Franklin Resources Inc. now owns 18,963 shares of the company’s stock worth $127,000 after acquiring an additional 7,027 shares in the last quarter. Sanctuary Advisors LLC purchased a new stake in Recursion Pharmaceuticals in the third quarter worth about $89,000. Finally, Geode Capital Management LLC increased its stake in shares of Recursion Pharmaceuticals by 13.7% during the third quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company’s stock valued at $35,803,000 after purchasing an additional 656,003 shares in the last quarter. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.